Are there candidates for high-dose chemotherapy in ovarian carcinoma?

BACKGROUND: Prognosis of advanced ovarian carcinomas (AOC) remains poor with a 5-year survival of 30%. Benefit from high-dose chemotherapy (HDC) in this disease has not been demonstrated to date. METHODS: To evaluate the value of HDC as consolidation treatment after surgery and platinum/taxane-based...

Descripción completa

Detalles Bibliográficos
Autores principales: Sabatier, Renaud, Gonçalves, Anthony, Bertucci, François, Capiello, Maria-Antonietta, Rousseau, Frédérique, Lambaudie, Eric, Chabannon, Christian, Viens, Patrice, Extra, Jean-Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3523074/
https://www.ncbi.nlm.nih.gov/pubmed/23072336
http://dx.doi.org/10.1186/1756-9966-31-87

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3523074/
https://www.ncbi.nlm.nih.gov/pubmed/23072336
http://dx.doi.org/10.1186/1756-9966-31-87

Ejemplares similares